Clinical Trial Update: Personalizing the Use of Pembrolizumab for Patients Who Have a Strong Response in Early Triple Negative Breast Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial update exploring personalization of pembrolizumab use for patients with a strong early response in triple-negative breast cancer; currently recrui…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: UNICANCER | Conditions: Breast Cancers, Triple Negative Breast Cancer (TNBC) | Phase 3 | Status: RECRUITING